Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year.
OpenAI chief executive Sam Altman, who provided the initial $180mn to seed the start-up, will put in more money in the series A. The company is in talks with family offices, venture capitalists and sovereign wealth funds, as well as a US “hyperscaler” data centre to provide computing power to run the AI models it uses to create and test its treatments.
In partnership with OpenAI, the start-up has built a bespoke AI model that designs proteins to temporarily turn regular cells into stem cells, which it says can reverse their ageing process.
您已閱讀18%（747字），剩餘82%（3386字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。